Data Monitoring Committees (DMCs) play a crucial role in the conducting of clinical trials to ensure the safety of study participants and to maintain a trial's scientific integrity. Generally accepted standards exist for DMC composition and operational conduct. However, some relevant issues are not specifically addressed in current guidance documents, resulting in uncertainties regarding optimal approaches for communication between the DMC, steering committee, and sponsors, release of information, and liability protection for DMC members. The Heart Failure Association (HFA) of the European Society of Cardiology (ESC), in collaboration with the Clinical Trials Unit of the European Heart Agency (EHA) of the ESC convened a meeting of international experts in DMCs for cardiovascular and cardiometabolic clinical trials to identify specific issues and develop steps to resolve challenges faced by DMCs.The main recommendations from the meeting relate to methodological consistency, independence, managing conflicts of interest, liability protection, and training of future DMC members. This paper summarizes the key outcomes from this expert meeting, and describes the core set of activities that might be further developed and ultimately implemented by the ESC, HFA, and other interested ESC constituent bodies. The HFA will continue to work with stakeholders in cardiovascular and cardiometabolic clinical research to promote these goals.
Introduction
Data Monitoring Committees (DMCs) play a key role in the conducting of clinical trials. Their primary obligation is to ensure the safety of study participants while maintaining trial integrity. 1 The DMCs achieve these functions primarily through reviewing interim safety and efficacy data, which assess the likelihood of harm, efficacy, or futility and the balance of risk vs. benefit, supplemented by existing knowledge and evidence external to the trial. Predefined statistical guidelines serve as a construct for decision-making, but DMCs may legitimately take action outside of these guidelines if the data are sufficiently compelling.
The DMCs are required by regulatory authorities for some, but not all studies. Studies requiring a DMC are typically large, later phase (usually phase 3), randomized, multicentre trials that evaluate mortality or major morbidity outcomes. Early phase or feasibility trials may also warrant a DMC if there is a potential for significant risks to subjects, or for complex, novel therapies where little may be known about the array of potential responses to the study agent. 2, 3 In addition, DMCs assembled for earlier phase studies may be responsible for multiple studies and often continue through phase 3, or they may be set up programme-wide for more than one study in parallel, to achieve continuity and maximize the DMC's experience with the therapy, which may be particularly important for novel regimens.
Generally accepted standards exist for DMC composition and operational conduct.
2 -5 Often, some relevant issues are not specifically addressed in current guidance documents or DMC charters, such as the communication structure between the DMC, steering committee, and sponsors (specifically when DMC recommendations are not followed), release of information, and liability protection for DMC members.
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC), in collaboration with the Clinical Trials Unit of the European Heart Agency (EHA) within the ESC recognized that independent, qualified, and experienced DMCs are an important vehicle for protecting the integrity of cardiovascular clinical trials, and these areas of uncertainty warranted discussion in an open forum. A meeting of international experts in DMCs for cardiovascular and cardiometabolic clinical trials was organized in 2015 and supported by the HFA to identify specific issues and advise steps to resolve challenges faced by DMCs. These societies acknowledge that identifying experienced individuals without significant conflicts of interest (i.e. potential for themselves or close personal connections to substantially benefit financially, professionally, or intellectually from the trial results) who are willing to participate in a DMC can be challenging. Finally, formal approaches are lacking to cultivate a greater number of appropriately experienced individuals to serve on DMCs, and the participants sought to use this forum to explore training approaches for future DMC leaders and members. This paper summarizes the key outcomes from this expert meeting.
Overview of the role of the Data Monitoring Committee
Data Monitoring Committees are primarily in place to ensure that patient safety is not compromised in an ongoing trial, and these . More complex considerations include stopping a trial early when there is overwhelming evidence (i.e. beyond a reasonable doubt and statistically supported) of a mortality benefit, such that the trial can be brought to rapid completion to expedite the availability of an effective therapy to the broader patient population, and to protect placebo/control group and future patients from the risk of delayed access to treatment. However, stopping early for benefit must be balanced against the risk of stopping too early on a 'random high' such that the results, once released, are misleading, uninterpretable, or insufficiently convincing to obtain regulatory approval/marketing authorization, change clinical practice, or satisfy payers. 6 -11 A trial stopped inappropriately early also faces the ethical problem of wasting the contributions of study participants if the data are ultimately not informative. The DMCs are also charged with protecting subjects from assuming unnecessary risks of clinical trial participation when a study appears to be futile (i.e. no chance for participating patients to benefit). Both industry and publicly funded trials may consider futility analysis to avoid wasting limited resources. However, declaring futility also assumes risks, such as the potential for missing a delayed treatment effect, an effect on important secondary endpoints, or definitive evidence of neutrality, which is important information especially for marketed products ( Table 1) .
Data Monitoring Committees may also provide recommendations for clinical trial operations to the extent that it impacts the DMC's ability to effectively monitor safety (e.g. timeliness of adjudication and obtaining source documentation, interim data, or event reporting) or if study integrity is at risk (e.g. minimizing missing data or dropouts, avoiding excessive regional variation in application of guideline-directed medical therapy). In addition, DMCs are becoming more proactive in recognizing problems that may impact study integrity as they are occurring in real-time. For example, the DMC in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT) reviewed characteristics and event rates of enrolled patients and made recommendations for subsequent enrolment as well as substudies to assess the severity of heart failure during the trial.
12 Furthermore, DMCs can also be responsible for other functions, such as recommending protocol adjustments for sample size or dose selection based on accrued data for studies with adaptive designs (i.e. where the study design can be modified at planned interim analyses, controlling for type I error) 13, 14 according to a valid, pre-specified plan.
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The DMC charter should include the responsibilities of the DMC, its structure, format for reports, statistical guidelines for recommending trial termination, contractual and indemnification information, processes for conducting open meetings (may include sponsor, steering committee, study personnel to facilitate sharing information relevant to study progress but interim data are not discussed) and closed sessions (limited to DMC members and the Stopping for futility should not be considered until at least one-half of the patients have been enrolled or one-half of the expected events have accumulated Should consider potential for loss of information on clinically relevant secondary endpoints, safety, a delayed treatment effect, definitive evidence of neutrality, or other important knowledge that may be generated by the trial Predictive and conditional power are useful concepts when considering futility PERFORM CONSENSUS II (stopped for futility + harm in other endpoints) ALTITUDE (stopped for futility + harm in other endpoints) EchoCRT data centre statistician because interim data are discussed), procedures to ensure confidentiality, and communication pathways. 4, 16, 17 Although charter templates have been proposed, 16 none have been uniformly adopted.
Importance of an independent Data Monitoring Committee
Independence is an attribute that is necessary for the DMC to perform its intended function. The DMC must be free to evaluate the data, request analyses, and make recommendations without . 
Conflicts of interest
Independence, as it relates to a DMC, can be complex. Steering committee members may propose potential candidates to serve on a DMC to the study sponsor or at a minimum, provide advice to the sponsor regarding the proposed DMC membership. Sponsors may have sole responsibility for choosing DMC members for trials without a steering committee (e.g. some phase 2 trials). It is pertinent to note that the term 'sponsor' is a single term but it can describe different entities or roles, depending on the study. The sponsor generally maintains final responsibility for the study, and may be the 'owner' of the data and results, but the sponsor is not necessarily the funding source, and the funding source is not necessarily a commercial company. It is important to note that DMCs are in place to protect patient safety and the overall integrity of the trial, which is in the interest of all stakeholders (i.e. patients, investigators, sponsors, and clinicians). However, remuneration for DMC services could be perceived as a conflict. Serving on a DMC requires considerable expertise and time commitment; thus, reasonable compensation commensurate with the time commitment and work involved is justified and in accordance with regulatory guidance, 3 although no compensation standards are available. Involving highly knowledgeable individuals on a DMC is desirable, but these individuals may be more likely than non-experts to have conflicts that need to be managed. 18 Although some conflicts may exist, DMC members should not have relationships that would result in significant financial, academic, intellectual, career, professional advancement, or other gains for themselves, their family members, or other close personal relationships based on the trial outcome.
17 Potential conflicts should be initially disclosed, and comprehensive reporting at routine intervals (i.e. every 6-12 months) should occur throughout the study. Using contract or academic research organizations, professional organizations such as the HFA, or other third parties independent of the sponsor to recommend or select DMC members and handle contracts and payments to DMC members has been proposed as a method to manage conflicts. The structure of the contractual relationship should be transparently provided in legal documents and the 'independence' of the third party should also be clearly described. This approach has not yet been systematically implemented, 4, 17 and whether it would promote more efficient management of potential conflicts or create reporting inefficiencies remains to be determined.
Liability
The issue of liability has been raised as a theoretical concern among DMC members.
17 -20 The lay public and legal personnel are unlikely to appreciate the nuances of interpreting fluctuations in interim data, and they may fail to understand how early data may be misleading. 19 In the context of a litigious society, DMC members may be appropriately concerned that uninformed misinterpretations of safety data could expose them to legal action. 20 Although actual cases have not yet been reported, many DMC members are concerned about potential legal action taken by patients who feel they have been harmed by participation in a study (and not adequately protected by the DMC), patients enrolled in placebo or standard therapy arms when the therapy tested is ultimately shown to be advantageous (i.e. holding DMC members liable for recommending that a study continue), or investors (e.g. either for allowing a study that was negative to continue or for not stopping a positive study earlier). members, which is a factor that may be a disincentive to DMC participation or unduly influence DMC decision-making. 20 Several authors have called for indemnification of DMC members by the study sponsor, which should include support to cover legal counsel for the DMC member independent of the sponsor's legal counsel to avoid legal conflicts of interest. 4, 19, 20 Communication with steering committee and sponsor Processes for communication should be clearly specified in the DMC charter. Opportunities for inadvertent, informal communication between the DMC and other parties involved in the trial should be minimized; for example, the DMC should avoid sponsor hospitality or advisory boards. Interactions among these groups should be conducted under a principle of maintaining confidentiality of interim results, 21 as release of interim data could bias investigators, study personnel, potential study enrolees, and the general public, and damage the integrity of the trial [e.g. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD), Simvastatin and Ezetimibe in Aortic Stenosis (SEAS)]. 22, 23 The steering committee or sponsor may discuss blinded data with the DMC when appropriate to inform them about the overall study progress, status of endpoint adjudication, or adverse event reporting. 24 In the context of adaptive designs, a limited group from the sponsor may interact with the DMC and have access to unblinded data, but beyond this purpose the authors strongly feel that unblinded data should never be shared with the study sponsor, steering committee, investigators, or other study personnel that are involved with potential protocol changes or whom have contact with investigators, unless the DMC is recommending premature termination, a position that is in agreement with regulatory standards (Figure 1) . 2, 3 Even with strict data confidentiality procedures in place, release of unblinded interim data for any purpose (e.g. planning of phase 3, regulatory submissions, business purposes) can have detrimental and irrecoverable effects on the integrity of an ongoing trial (e.g. naltrexone/bupropion). 25 While representation of government sponsors, including project officers and other administrative staff, during DMC meetings sometimes occurs, 24 the authors of this paper discourage such involvement as the government sponsor's role is to select centres, monitor progress, and financially support a clinical trial. Minimally, unblinded staff should not participate in discussions or decisions to modify the protocol or be in a position to directly or indirectly, knowingly or unknowingly, convey information about interim data to others involved in the study.
In special circumstances, regulatory agencies may request information from the sponsor on interim, unblinded data when adverse events of concern have been observed in other studies of the same drug, drug class, or device. The DMC may provide this information to regulatory agencies if the sponsor agrees with the request. However, regulatory actions taken in response to the interim data may have major implications on the ability of the study to continue to completion. Thus, before undertaking this approach, regulatory agencies should give careful consideration to all factors, including (denoted by thicker border), where one-way input to the DMC can be provided by regulatory authorities or external DMCs, usually with the knowledge or approval of the steering committee or sponsor. One-way output of unblinded data to the steering committee or sponsor only occurs when premature termination is recommended, although a partial flow of unblinded information may occur between a small group of people within the steering committee or sponsor in an adaptive design. The only two-way communication of blinded data occurs between the DMC and the data centre statistician. *Regulatory bodies may request (with the knowledge/approval of the steering committee or sponsor) that the DMC monitor specific events if concerns emerge from external trials or data. † Other DMCs may suggest specific events for monitoring if concerns emerge from ongoing external trials (with the knowledge/approval of the steering committee or sponsor). ‡ Blinded data may be communicated between the DMC and steering committee and/or sponsor when the DMC has concerns about issues that affect the quality of the study (e.g. concerns about data integrity, timeliness of reporting adverse events, concerns about the nature of the patients enrolled). ARO, academic research organization; CRO, contract research organization; EC, ethics committee; IRB, institutional review board. the strength of the safety signal, quantity of the data, potential for exposure of the general public (e.g. if the study involves a commercially available drug), potential for the action to result in premature cessation of the study, and loss of the ability to achieve a precise answer to the research question of interest. Rather than request access to unblinded data, it may be preferable for regulatory agencies to communicate with the sponsor and request that the DMC undertake closer monitoring for a specific adverse event and allow the DMC to review the data and make appropriate recommendations regarding continuation or termination of the study. However, this may lead to problems in practice, and regulatory authorities may decide to take their own, independent, responsibility [e.g. Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE)]. 26, 27 Clear communication between the regulators, sponsor, steering committee, and DMC can help to ensure that optimal decisions are made that both protect patient safety and trial integrity. These groups should jointly develop processes to streamline interactions (e.g. sharing statistical analysis plans rather than unblinded data in certain circumstances), which might help resolve difficult situations without compromising the role and responsibilities of either group. The DMC acts in an advisory capacity to the executive leadership of the trial and the study sponsor. They make recommendations, which the steering committee and/or sponsor must decide whether or not to follow. Cases have arisen where steering committees or sponsors chose not to follow the recommendation of the DMC. 28 Similarly, cases have arisen where sponsors have chosen to release information without involving the DMC (e.g. RECORD, SEAS, naltrexone/bupropion). 22, 23, 25, 29 The DMC charter should describe the course of action that will be taken in the case of such disagreements (e.g. clear reporting structure to delineate which party has final decision-making capabilities, processes that will be implemented to resolve disagreements and achieve consensus such as use of a third-party expert panel to act as arbitrator).
Importance of an experienced Data Monitoring Committee
The need for an experienced DMC, particularly the committee chair, has been underscored by other authors 4, 17 and regulatory guidance documents. 2, 3 DMCs should ideally comprise three to five Previous participation in steering committees is desirable preparation for individuals interested in serving on a DMC. Important knowledge is generated through this experience regarding clinical trial protocol design, study execution and operations, and DMC interactions that cannot be obtained through seminars, training modules, or reading textbooks or journal articles on the topic. 30 The need to prepare more individuals for DMC service has been acknowledged ( Table 2) . 4, 17, 30, 31 Membership of a DMC involves reviewing data and making decisions that can be highly nuanced, using concepts that are challenging to convey in didactic type training programs. 30 Mentoring programmes are one mechanism that could be implemented to provide opportunity for individuals to participate as non-voting DMC members, alongside experienced DMC members, to gain the skills required for independent DMC service. These programmes should be extended to individuals at any career stage. Targeting early career individuals will provide an opportunity to realize many years of qualified service for the training investment. However, late career individuals represent a valuable resource in terms of clinical and research experience, and may have fewer competing responsibilities than early or mid-career investigators. Sharing DMC experiences after a trial has concluded through publications 7,28,32 -34 or other avenues of dissemination (e.g. supplementary material available with the primary publication, postings on clinical trial registry database websites) is also encouraged as a means to educate current and future DMC members and to achieve transparency in the DMC process. 
Role of the Heart Failure Association and European Heart Agency
A key objective of the HFA workshop was to identify areas where HFA, ESC constituent bodies, and the EHA could contribute to strengthening the utilization of DMCs in cardiovascular and metabolic clinical trials. Several areas of potential involvement were identified and will be further explored and developed by the leadership of these organizations.
Develop registry of Data Monitoring Committee members
The importance of access to experienced DMC members was a recurring theme raised during the workshop. Members of a DMC may be selected on the basis of recommendations from the steering committee or industry sponsor, but smaller companies or newcomers to the field may have less knowledge about suitable individuals for DMC service or may lack access to them. The HFA in collaboration with other ESC constituent bodies (i.e. the Clinical Trials Unit of the ESC) could create a registry of potential DMC members, including information on past steering or DMC committee experience and unique expertise they may have in specific disease states or novel therapeutics. This would be a valuable resource for steering committees and sponsors, while also serving to enhance the independence of the DMC as potential members would be first identified by querying the HFA DMC registry rather than by direct nomination from the sponsor or steering committee.
information would also be maintained in the registry, and individuals with conflicts that could not be adequately managed (according to clearly pre-defined criteria) would be excluded from selection. For individuals where potential, but manageable, conflicts were present, the HFA or other relevant ESC constituent bodies could advise steps to further mitigate the conflict (e.g. discontinue consultant or advisory activities during the course of the trial). Finally, the HFA or other relevant ESC constituent bodies could lobby sponsors to provide indemnification with language that protects DMC members from liability and ensures that individual legal counsel will be provided in the event it is needed.
Develop training modules and facilitate mentorship programmes
The suggested DMC registry would also provide infrastructure to match investigators interested in gaining DMC experience with seasoned DMC members willing to provide mentorship opportunities. The mentorship programme would combine web-based training modules with real-life, hands-on experience within a DMC ( Table 2 ). Trainees would be non-voting members of the DMC and would gain exposure to all aspects of the DMC process, including developing a charter, regulatory requirements and expectations for DMCs, reviewing DMC reports, participating in open and closed DMC sessions, and exposure to communication pathways between the DMC, sponsors, steering committee, investigators, and regulatory bodies. The HFA encourages publication of DMC proceedings after completion of those trials where 'lessons learned' would be of value for future DMCs. The HFA, and more broadly the ESC, may be positioned to facilitate the transparent reporting and public dissemination of this information through its journal, website, and annual meeting.
Conclusion
Data monitoring committees play a vital role in protecting human subjects enrolled in clinical trials, and they instil confidence that the integrity of the trial is intact and the data are reliable. The increasingly widespread use of DMCs is accompanied by concerns related to their independence, conflicts of interest, liability protection, and a lack of qualified individuals for DMC service. The topic of DMCs is often discussed in the literature and academic circles, but few efforts have been adopted to address these challenges. During the workshop, the HFA suggested a core set of activities that might be further developed and ultimately implemented to impact upon these areas. The HFA will continue to advise stakeholders in cardiovascular and cardiometabolic clinical research to promote the integration of independent DMCs in clinical trials where needed, protect the interests of those serving as DMC members, and cultivate highly skilled individuals for DMC service.
